JP2019507135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507135A5 JP2019507135A5 JP2018540141A JP2018540141A JP2019507135A5 JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5 JP 2018540141 A JP2018540141 A JP 2018540141A JP 2018540141 A JP2018540141 A JP 2018540141A JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding substance
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 230000027455 binding Effects 0.000 claims 15
- 239000000126 substance Substances 0.000 claims 15
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- 230000035693 Fab Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- PQEJXGNZBLONLG-XJDOXCRVSA-N (2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O PQEJXGNZBLONLG-XJDOXCRVSA-N 0.000 claims 1
- 229920002395 Aptamer Polymers 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010027665 Immune disorder Diseases 0.000 claims 1
- 206010021425 Immune system disease Diseases 0.000 claims 1
- 229940047124 Interferons Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 229940047122 Interleukins Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000002463 transducing Effects 0.000 claims 1
Claims (16)
- 3つの相補性決定領域(CDR1、CDR2、およびCDR3)を含む少なくとも1つのターゲティング部分を含むCD8結合物質であって、
(a)CDR1が、GFTFDDYAMS(配列番号12)またはGFTFDDYAIG(配列番号13)から選択されるアミノ酸配列を含み、
(b)CDR2が、TINWNGGSAEYAEPVKG(配列番号14)またはCIRVSDGSTYYADPVKG(配列番号15)から選択されるアミノ酸配列を含み、かつ
(c)CDR3が、KDADLVWYNLS(配列番号16)またはKDADLVWYNLR(配列番号17)、およびAGSLYTCVQSIVVVPARPYYDMDY(配列番号18)から選択されるアミノ酸配列を含む、
CD8結合物質。 - 前記ターゲティング部分が、完全長抗体、単一ドメイン抗体、組換え重鎖のみで構成される抗体(VHH)、単鎖抗体(scFv)、サメ重鎖のみで構成される抗体(VNAR)、マイクロタンパク質、darpin、アンチカリン、アドネクチン、アプタマー、Fv、Fab、Fab’、F(ab’)2、ペプチド模倣分子、受容体に対する天然リガンド、または合成分子である、請求項1に記載のCD8結合物質。
- 前記ターゲティング部分が、単一ドメイン抗体である、請求項1または2に記載のCD8結合物質。
- 前記ターゲティング部分が、VHH、ヒト化VHH、またはラクダ化VHHを含む、請求項3に記載のCD8結合物質。
- 前記ターゲティング部分が、GFTFDDYAMS(配列番号12)のアミノ酸配列を含むCDR1、TINWNGGSAEYAEPVKG(配列番号14)のアミノ酸配列を含むCDR2、およびKDADLVWYNLS(配列番号16)のアミノ酸配列を含むCDR3を含む、請求項1〜4のいずれか1項に記載のCD8結合物質。
- 配列番号19と少なくとも90%の配列類似性を有するアミノ酸配列を含む、請求項5に記載のCD8結合物質。
- 前記ターゲティング部分が、GFTFDDYAMS(配列番号12)のアミノ酸配列を含むCDR1、TINWNGGSAEYAEPVKG(配列番号14)のアミノ酸配列を含むCDR2、およびKDADLVWYNLR(配列番号17)のアミノ酸配列を含むCDR3を含む、請求項1〜4のいずれか1項に記載のCD8結合物質。
- 配列番号20と少なくとも90%の配列類似性を有するアミノ酸配列を含む、請求項7に記載のCD8結合物質。
- 前記ターゲティング部分が、GFTFDDYAIG(配列番号13)のアミノ酸配列を含むCDR1、CIRVSDGSTYYADPVKG(配列番号15)のアミノ酸配列を含むCDR2、およびAGSLYTCVQSIVVVPARPYYDMDY(配列番号18)のアミノ酸配列を含むCDR3を含む、請求項1〜4のいずれか1項に記載のCD8結合物質。
- 配列番号21と少なくとも90%の配列類似性を有するアミノ酸配列を含む、請求項9に記載のCD8結合物質。
- 前記CD8結合物質が、1種または複数のシグナル伝達物質を含む、請求項1〜10のいずれか1項に記載のCD8結合物質。
- 前記シグナル伝達物質が、インターフェロン、インターロイキン、腫瘍壊死因子、およびそれらの改変された型の1種または複数から選択される、請求項11に記載のCD8結合物質。
- 前記CD8結合物質が、1つまたは複数の追加のターゲティング部分を含む、請求項1〜12のいずれか1項に記載のCD8結合物質。
- 前記1つまたは複数の追加のターゲティング部分が、腫瘍抗原または免疫細胞上の抗原を認識するまたは機能的に調節する、請求項13に記載のCD8結合物質。
- 癌、感染症、免疫異常、および/または自己免疫疾患のうちの1種または複数を処置するための薬物の製造のための請求項1〜14のいずれか1項に記載のCD8結合物質の使用。
- 請求項1〜15のいずれか1項に記載のCD8結合物質および薬学的に許容可能な賦形剤または担体を含む医薬組成物。
Applications Claiming Priority (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291779P | 2016-02-05 | 2016-02-05 | |
US201662291772P | 2016-02-05 | 2016-02-05 | |
US201662291776P | 2016-02-05 | 2016-02-05 | |
US201662291769P | 2016-02-05 | 2016-02-05 | |
US201662291774P | 2016-02-05 | 2016-02-05 | |
US62/291,774 | 2016-02-05 | ||
US62/291,772 | 2016-02-05 | ||
US62/291,769 | 2016-02-05 | ||
US62/291,779 | 2016-02-05 | ||
US62/291,776 | 2016-02-05 | ||
US201662335979P | 2016-05-13 | 2016-05-13 | |
US201662335880P | 2016-05-13 | 2016-05-13 | |
US201662335965P | 2016-05-13 | 2016-05-13 | |
US201662336030P | 2016-05-13 | 2016-05-13 | |
US201662335968P | 2016-05-13 | 2016-05-13 | |
US62/335,968 | 2016-05-13 | ||
US62/336,030 | 2016-05-13 | ||
US62/335,965 | 2016-05-13 | ||
US62/335,880 | 2016-05-13 | ||
US62/335,979 | 2016-05-13 | ||
US201662353607P | 2016-06-23 | 2016-06-23 | |
US62/353,607 | 2016-06-23 | ||
US201662411805P | 2016-10-24 | 2016-10-24 | |
US62/411,805 | 2016-10-24 | ||
PCT/EP2017/052553 WO2017134306A1 (en) | 2016-02-05 | 2017-02-06 | Cd8 binding agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019507135A JP2019507135A (ja) | 2019-03-14 |
JP2019507135A5 true JP2019507135A5 (ja) | 2020-03-19 |
JP6991979B2 JP6991979B2 (ja) | 2022-03-04 |
Family
ID=57995193
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
JP2018540141A Active JP6991979B2 (ja) | 2016-02-05 | 2017-02-06 | Cd8結合物質 |
JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Clec9a結合物質 |
JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Clec9a結合物質 |
JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
Country Status (8)
Country | Link |
---|---|
US (6) | US10988538B2 (ja) |
EP (7) | EP4059957A1 (ja) |
JP (6) | JP7166923B2 (ja) |
CN (9) | CN117024599A (ja) |
CA (4) | CA3013551A1 (ja) |
DK (1) | DK3411065T3 (ja) |
ES (1) | ES2877568T3 (ja) |
WO (4) | WO2017134306A1 (ja) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024599A (zh) * | 2016-02-05 | 2023-11-10 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
CA3023881A1 (en) * | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
EP3576765A4 (en) | 2017-02-06 | 2020-12-02 | Orionis Biosciences, Inc. | TARGETED ENGINEERING INTERFERON AND USES OF IT |
KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
AU2018298063A1 (en) | 2017-07-03 | 2020-02-20 | Torque Therapeutics, Inc. | Polynucleotides encoding immunostimulatory fusion molecules and uses thereof |
CN111164100B (zh) | 2017-08-03 | 2024-03-12 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
MX2020001513A (es) * | 2017-08-09 | 2020-08-20 | Orionis Biosciences Inc | Agentes de union a clec9a y su uso. |
JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Cd8結合物質 |
JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Pd-1およびpd-l1結合物質 |
AU2018318698A1 (en) * | 2017-08-16 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1 |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
EP3743448A4 (en) * | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
AU2019215440A1 (en) | 2018-02-05 | 2020-08-27 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
US11987629B2 (en) | 2018-06-01 | 2024-05-21 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
KR102263643B1 (ko) * | 2018-07-24 | 2021-06-10 | 주식회사 굳티셀 | 면역 관련 질환의 예방 또는 치료용 조성물 |
EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | IMAGING COMPOSITIONS AND METHODS |
EP3833391A4 (en) * | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES |
EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
EP3848397A4 (en) * | 2018-09-04 | 2022-07-20 | Nanjing Umab-Biopharma Co., Ltd. | FUSION PROTEIN AND ITS APPLICATION IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF A TUMOR AND/OR A VIRAL INFECTION |
AU2019356573A1 (en) * | 2018-10-11 | 2021-05-27 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
EP3890773A4 (en) * | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
EP3898677A1 (en) * | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
AU2019406453A1 (en) * | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional molecule directed against human PD-1 |
JP2022516964A (ja) * | 2019-01-07 | 2022-03-03 | シャタック ラボ,インコーポレイテッド | ガンマデルタt細胞を調節するためのヘテロ二量体タンパク質 |
CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
CN113613674A (zh) * | 2019-03-15 | 2021-11-05 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
EP3946410A4 (en) | 2019-03-28 | 2023-06-28 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
EP3946408A4 (en) * | 2019-03-28 | 2023-06-14 | Orionis Biosciences, Inc. | CHEMICAL PROTEINS AND CHEMICAL PROTEIN COMPLEXES AGAINST FMS-LIKE TYROSINE KINASE 3 (FLT3) |
CA3133831A1 (en) * | 2019-03-28 | 2020-10-01 | Nikolai Kley | Clec9a-based chimeric protein complexes |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
JP2022534716A (ja) | 2019-05-27 | 2022-08-03 | イマティクス ユーエス,アイエヌシー. | ウイルスベクターおよびその養子細胞療法における使用 |
JP2022537515A (ja) * | 2019-06-10 | 2022-08-26 | アポロミクス インコーポレイテッド(ハンジョウ) | 抗体-インターロイキン融合タンパク質および使用方法 |
WO2021037184A1 (zh) * | 2019-08-30 | 2021-03-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4174087A1 (en) * | 2020-06-30 | 2023-05-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Drug for treating tumor |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
JP2023544890A (ja) | 2020-10-13 | 2023-10-25 | ヤンセン バイオテツク,インコーポレーテツド | 分化抗原群iv及び/又はviiiを調節するための生物工学的に作製されたt細胞媒介免疫、材料及び他の方法 |
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
CN116635519A (zh) * | 2020-11-26 | 2023-08-22 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
MX2023005930A (es) * | 2020-11-26 | 2023-05-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. |
CN112724199B (zh) * | 2020-12-30 | 2023-01-24 | 郑州大学 | 亲和Clec9a的多肽及其应用 |
AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023154785A2 (en) * | 2022-02-10 | 2023-08-17 | Orionis Biosciences, Inc. | Il-2 trap molecules |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
JP2024047762A (ja) | 2022-09-27 | 2024-04-08 | セイコーエプソン株式会社 | 成形用材料 |
CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
DE69007975T2 (de) | 1989-08-22 | 1994-07-21 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
DE69032484D1 (de) | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
JP2763958B2 (ja) | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ,インコーポレイテッド | 核酸リガンド |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
SE9201966D0 (sv) | 1992-06-25 | 1992-06-25 | Trion Forskning & Utveckling | Interleukin-1beta deletion mutant |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
WO1996002561A1 (en) | 1994-07-20 | 1996-02-01 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
AU6961796A (en) | 1995-09-12 | 1997-04-01 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
DE69632235T2 (de) | 1995-10-18 | 2004-08-26 | Akzo Nobel N.V. | Newcastle-Krankheitsvirus-Kombinationsimpfstoff |
US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5986059A (en) | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
ES2260009T3 (es) | 1999-05-05 | 2006-11-01 | Phylogica Limited | Aislamiento de moduladores biologicos a partir de bancos de fragmentos genicos biodiversos. |
AU4761100A (en) | 1999-05-26 | 2000-12-18 | Kalle Saksela | Methods and materials for generating sh3 domains with tailored binding properties |
JP2001026545A (ja) | 1999-07-09 | 2001-01-30 | Takara Shuzo Co Ltd | 免疫応答活性化製剤 |
US6936704B1 (en) | 1999-08-23 | 2005-08-30 | Dana-Farber Cancer Institute, Inc. | Nucleic acids encoding costimulatory molecule B7-4 |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
US6613756B2 (en) | 2000-05-05 | 2003-09-02 | Wisconsin Alumni Research Foundation | Use of tetracycline derivatives in treating multiple sclerosis |
SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
GB0014356D0 (en) | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
US20020025304A1 (en) | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
ATE472554T1 (de) | 2000-08-30 | 2010-07-15 | Penn State Res Found | Aminosäureaustauschmutanten von interleukin 13 |
DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
AU2003282724B2 (en) | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
AU2003298015A1 (en) | 2002-12-05 | 2004-06-30 | Pdl Biopharma, Inc. | Methods of treatment of ulcerative colitis with anti-cd3 antibodies |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
AU2003300133B2 (en) | 2002-12-31 | 2008-11-13 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
DE602004031589D1 (de) | 2003-01-07 | 2011-04-14 | Dyax Corp | Kunitz-domäne-bibliothek |
ATE455127T1 (de) | 2003-05-31 | 2010-01-15 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
EA010350B1 (ru) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
CN100523739C (zh) | 2004-07-12 | 2009-08-05 | 三菱电机株式会社 | 光学式编码器 |
DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
JP2008520717A (ja) | 2004-11-19 | 2008-06-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多発性硬化症についての処置 |
WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
PL1888641T3 (pl) | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
KR101600225B1 (ko) * | 2005-06-08 | 2016-03-04 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
GB0513047D0 (en) | 2005-06-27 | 2005-08-03 | Thermo Finnigan Llc | Electronic ion trap |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
RU2549676C2 (ru) | 2007-06-01 | 2015-04-27 | Юниверсити Оф Мэрилэнд, Балтимор | СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
MX2010003099A (es) | 2007-09-21 | 2010-05-17 | Univ California | Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales. |
ES2542033T3 (es) | 2007-11-29 | 2015-07-29 | Molecular Health Gmbh | Receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso |
US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CA2734908A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
CN102245623A (zh) | 2008-12-08 | 2011-11-16 | 康普里斯有限公司 | 单链反向平行卷曲型螺旋蛋白 |
TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
CN102361646A (zh) * | 2009-03-23 | 2012-02-22 | 沃尔特及伊莱萨霍尔医学研究院 | 调节免疫应答的化合物和方法 |
JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
EP2473186A4 (en) * | 2009-08-31 | 2013-07-10 | Ibc Pharmaceuticals Inc | BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF |
EP2475397A1 (en) | 2009-09-10 | 2012-07-18 | Cytos Biotechnology AG | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
SI2673294T1 (sl) | 2011-02-10 | 2016-08-31 | Roche Glycart Ag | Mutirani polipeptidi interlevkina-2 |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
SE535863C2 (sv) | 2011-07-18 | 2013-01-22 | Atlas Copco Ind Tech Ab | Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål |
WO2013053008A2 (en) * | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
EP3559049A4 (en) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF |
KR102050119B1 (ko) | 2012-01-20 | 2019-11-28 | 브이아이비 브이지더블유 | 표적화된 돌연변이 알파-나선형 다발 사이토카인 |
JP6195855B2 (ja) * | 2012-03-03 | 2017-09-13 | イミュンジーン,インコーポレーテッド | 工学的に作製した抗体−インターフェロン変異体融合分子 |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
CA2915412A1 (en) | 2012-06-14 | 2013-12-19 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
US10301389B2 (en) | 2012-06-15 | 2019-05-28 | Imaginab, Inc. | Antigen binding constructs to CD3 |
CN102775502A (zh) * | 2012-08-16 | 2012-11-14 | 天津禹王生物医药科技有限公司 | α干扰素融合蛋白 |
WO2014164553A1 (en) | 2013-03-13 | 2014-10-09 | Imaginab, Inc. | Antigen binding constructs to cd8 |
US10537638B2 (en) | 2013-03-15 | 2020-01-21 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
CN113248615A (zh) | 2013-07-05 | 2021-08-13 | 根马布股份公司 | 人源化或嵌合cd3抗体 |
EP3299466B1 (en) | 2013-07-18 | 2019-09-11 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
US9914759B2 (en) | 2013-07-19 | 2018-03-13 | Vib Vzw | Targeted modified TNF family members |
DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
JP6475712B2 (ja) | 2013-07-19 | 2019-02-27 | ヴィブ ブイゼットダブリュー | サイトカインアンタゴニストの標的化 |
HRP20212023T1 (hr) * | 2013-08-08 | 2022-04-01 | Cytune Pharma | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni |
JP6508785B2 (ja) * | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
WO2016002263A1 (ja) | 2014-06-30 | 2016-01-07 | ソニー株式会社 | 無線通信装置、無線通信方法及びプログラム |
KR20230028807A (ko) * | 2014-06-30 | 2023-03-02 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
CN106462263B (zh) | 2014-07-11 | 2020-07-17 | 株式会社和冠 | 位置指示器、位置检测装置以及位置检测装置的输入控制方法 |
WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
MX2017001597A (es) | 2014-08-05 | 2017-11-17 | Cb Therapeutics Inc | Anticuerpos anti-pd-l1. |
EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
ES2727154T3 (es) | 2014-10-24 | 2019-10-14 | Astrazeneca Ab | Combinación |
KR102639037B1 (ko) * | 2014-10-29 | 2024-02-20 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 인터페론 α2b 변이체 |
CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
CN117024599A (zh) * | 2016-02-05 | 2023-11-10 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
-
2017
- 2017-02-06 CN CN202310688724.9A patent/CN117024599A/zh active Pending
- 2017-02-06 WO PCT/EP2017/052553 patent/WO2017134306A1/en active Application Filing
- 2017-02-06 EP EP22160584.3A patent/EP4059957A1/en active Pending
- 2017-02-06 EP EP17704697.6A patent/EP3411398B1/en active Active
- 2017-02-06 CA CA3013551A patent/CA3013551A1/en active Pending
- 2017-02-06 US US16/075,312 patent/US10988538B2/en active Active
- 2017-02-06 CN CN201780021480.1A patent/CN109071632B/zh active Active
- 2017-02-06 JP JP2018541289A patent/JP7166923B2/ja active Active
- 2017-02-06 JP JP2018541357A patent/JP7030704B2/ja active Active
- 2017-02-06 CA CA3013554A patent/CA3013554A1/en active Pending
- 2017-02-06 ES ES17703965T patent/ES2877568T3/es active Active
- 2017-02-06 CN CN201780021559.4A patent/CN109071627B/zh active Active
- 2017-02-06 US US16/075,317 patent/US11236166B2/en active Active
- 2017-02-06 CN CN202310688728.7A patent/CN116769054A/zh active Pending
- 2017-02-06 CN CN202310792382.5A patent/CN116854826A/zh active Pending
- 2017-02-06 CA CA3013555A patent/CA3013555A1/en active Pending
- 2017-02-06 DK DK17703965.8T patent/DK3411065T3/da active
- 2017-02-06 EP EP17703965.8A patent/EP3411065B1/en active Active
- 2017-02-06 CA CA3013558A patent/CA3013558A1/en active Pending
- 2017-02-06 EP EP17705564.7A patent/EP3411407B1/en active Active
- 2017-02-06 EP EP21165264.9A patent/EP3909978A1/en active Pending
- 2017-02-06 JP JP2018540141A patent/JP6991979B2/ja active Active
- 2017-02-06 WO PCT/EP2017/052545 patent/WO2017134302A2/en active Application Filing
- 2017-02-06 US US16/075,318 patent/US11001631B2/en active Active
- 2017-02-06 CN CN202211603239.9A patent/CN115850521A/zh active Pending
- 2017-02-06 WO PCT/EP2017/052544 patent/WO2017134301A1/en active Application Filing
- 2017-02-06 CN CN201780021264.7A patent/CN109071663B/zh active Active
- 2017-02-06 CN CN201780021194.5A patent/CN108883180B/zh active Active
- 2017-02-06 JP JP2018541133A patent/JP7236273B2/ja active Active
- 2017-02-06 WO PCT/EP2017/052550 patent/WO2017134305A1/en active Application Filing
- 2017-02-06 EP EP21195070.4A patent/EP3998281A1/en active Pending
- 2017-02-06 EP EP17704207.4A patent/EP3411397A1/en not_active Withdrawn
- 2017-02-06 CN CN202310792348.8A patent/CN116813799A/zh active Pending
-
2020
- 2020-12-21 US US17/128,599 patent/US20210139586A1/en active Pending
-
2021
- 2021-04-05 US US17/222,043 patent/US20220356253A1/en active Pending
- 2021-12-17 US US17/554,180 patent/US20220177586A1/en active Pending
-
2022
- 2022-02-22 JP JP2022025686A patent/JP7386277B2/ja active Active
- 2022-07-08 JP JP2022110687A patent/JP2022153437A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019507135A5 (ja) | ||
JP2019507762A5 (ja) | ||
JP2019506867A5 (ja) | ||
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
JP2019510478A5 (ja) | ||
JP2018512138A5 (ja) | ||
JP2019531084A5 (ja) | ||
JP2017535257A5 (ja) | ||
JP2018508483A5 (ja) | ||
JP2017048240A5 (ja) | ||
JP2015163068A5 (ja) | ||
JP2017519759A5 (ja) | ||
JP2018512175A5 (ja) | ||
JP2021503455A5 (ja) | ||
JP2013506428A5 (ja) | ||
IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
JP2017530691A5 (ja) | ||
JP2009506791A5 (ja) | ||
JP2020517239A5 (ja) | ||
JP2021508707A5 (ja) | ||
JP2013519364A5 (ja) | ||
JP2020502271A5 (ja) | ||
JP2011207882A5 (ja) | ||
JP2019512207A5 (ja) | ||
Imakiire et al. | Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen |